Heather Ruth Cassell

Interests

No activities entered.

Courses

Scholarly Contributions

Journals/Publications

• Greenhawt, M., Sindher, S. B., Wang, J., O'Sullivan, M., du Toit, G., Kim, E. H., Albright, D., Anvari, S., Arends, N., Arkwright, P. D., Bégin, P., Blumchen, K., Bourrier, T., Brown-Whitehorn, T., Cassell, H., Chan, E. S., Ciaccio, C. E., Deschildre, A., Divaret-Chauveau, A., , Dorris, S. L., et al. (2023). Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. The New England journal of medicine, 388(19), 1755-1766.
  More info

  No approved treatment for peanut allergy exists for children younger than 4 years of age, and the efficacy and safety of epicutaneous immunotherapy with a peanut patch in toddlers with peanut allergy are unknown.
• Cassell, H. R., & Katial, R. K. (2009). Intranasal antihistamines for allergic rhinitis: examining the clinical impact. Allergy and asthma proceedings, 30(4), 349-57.
  More info

  Allergic rhinitis is likely the most common medical complaint to a clinical allergist and immunologist affecting between 10 and 30% of all adults. This disease causes significant impact on quality of life as well as creating a financial burden on society with decreased work productivity and medication costs. Often, many allergy sufferers do not adhere to the medication recommendations provided by their physician most often because these therapies have not provided relief. Although in the past, the mainstay of treatment for allergic rhinitis has been environmental avoidance, immunotherapy, nasal corticosteroids, and oral antihistamines, the most recent rhinitis diagnosis parameters published by the American Academy of Allergy, Asthma and Immunology have also discussed the importance of other often overlooked therapies. More specifically, the new guidelines discuss a place for the use of intranasal antihistamines as first-line therapy as well as potentially providing superior relief to second-generation oral antihistamines. The guidelines also identify the biphasic nature of the allergic response with both phases consisting of nasal pruritus, sneezing, rhinorrhea, and congestion with the late phase predominated by nasal congestion. It is important to understand how intranasal antihistamines fit into these latest guidelines as first-line therapy and to understand how they may be beneficial to the symptoms associated with allergic rhinitis. It is equally important to identify the individuals who have had less success with their current therapies to determine if intranasal antihistamines would be an important adjunct in therapy.
• Sanders, H., Davis, M. F., Duncan, B., Meaney, F. J., Haynes, J., & Barton, L. L. (2003). Use of complementary and alternative medical therapies among children with special health care needs in southern Arizona. Pediatrics, 111(3), 584-7.
  More info

  The objective of this study was to assess the frequency and type of complementary and alternative medicine (CAM) therapies used by families of children with special health care needs in southern Arizona, as well as the correlates of their use.

Poster Presentations

• Cassell, H., Martinez, F., Stern, D., & Wright, A. L. (2018, March). Early Onset Eczema and the Association with Early Onset Asthma. American Academy of Allergy, Asthma, and Immunology. Orlando, FL.